Blogs
Kingsgate Consolidated (ASX: KCN): One of the Most Undervalued ASX Gold Producers
Revenue and EPS are expected to grow through FY27–FY28, although earnings remain sensitive to gold prices and mining costs. Based on FY26 normalised EPS of A$0.76 and a 10–12x P/E, fair value is estimated at A$7.6–9.1 per share.
.webp&w=828&q=75)
Golden Deeps (ASX: GED):10-Month Descending Channel Ends as High-Grade Graceland Results Surge
Golden Deeps is advancing deeper drilling at Graceland after encouraging copper, silver and zinc results. Fresh assays and new targets have strengthened interest in the Namibian exploration program, while upcoming drilling will test the discovery’s potential scale.
What is Market Capitalisation? ASX Small, Mid and Large Cap Stocks Explained
Learn what market capitalisation means, how ASX market cap is calculated, and the key differences between small-, mid-, and large-cap stocks when comparing Australian-listed companies.
IGO (ASX: IGO): Operational Discipline and Strategic Refocus Amid Energy Transition
IGO (ASX: IGO) delivers strong FY26 results with disciplined execution, expanding margins at Greenbushes and Nova, and strategic portfolio optimisation aligned with global energy transition.
AVITA Medical INC. (ASX: AVH): Technical Rally Driven by Solid Fundamentals
AVITA Medical is strengthening its commercial position as revenue growth improves, cash burn reduces, and its regenerative medicine portfolio expands. The company’s progress in product adoption and operational efficiency keeps it positioned as a speculative healthcare growth story.
.webp&w=828&q=75)
ASX 200 vs All Ordinaries: What’s the Difference for Investors?
Learn the key differences between the ASX 200 and All Ordinaries, including company coverage, investment uses, and how each index helps investors understand the Australian share market.
.webp&w=828&q=75)
Bannerman Energy (ASX: BMN): Strategic Financing and Etango Execution Momentum
Bannerman Energy (ASX: BMN) advances Etango uranium project with CNNC financing, strong early works execution, and rising uranium prices, positioning as a leveraged mid-cap growth play in a buoyant nuclear fuel market.
.webp&w=828&q=75)
Felix Gold (ASX: FXG) Surges Past Resistance on High Volume as US Antimony Extraction Momentum Accelerates
Felix Gold is advancing Alaskan antimony and gold assets, with potential US$18 million DOE pilot-processing funding driving investor interest. The non-dilutive funding could support domestic antimony supply, though project execution, permitting and financing risks remain.
Pro Medicus (ASX: PME): Scaling Global Leadership in Enterprise Imaging and AI‑Driven Diagnostics
Pro Medicus (ASX: PME) delivers record revenue growth, expanding margins, and accelerating AI‑driven innovation, reinforcing its global leadership in enterprise imaging and cloud‑based diagnostics.
.webp&w=828&q=75)
BlinkLab (ASX: BB1) Gains Momentum: AI Screening Platform Meets a High-Volume BB1 Breakout
BlinkLab (ASX: BB1) is advancing its autism and ADHD assessment technology through clinical studies, FDA validation work, and research partnerships. Recent technical strength reflects growing investor interest, though regulatory and commercial risks remain.
EQT Holdings (ASX: EQT): Margin Expansion and Regulatory Resilience Through Diversified Growth
EQT Holdings (ASX: EQT) delivers strong margin expansion, organic growth and robust cash generation across its trustee service lines, while navigating regulatory headwinds with discipline and strategic clarity.
Life360 INC. (ASX:360): Stronger Growth, Expanding Margins and a Bullish Channel Under Pressure
Life360 delivers powerful subscription and advertising growth, expanding margins and accelerating global penetration. Strong MAU momentum, rising Paying Circles, and a breakout technical setup reinforce the company’s position as a high‑growth digital safety leader.
.webp&w=828&q=75)
Locksley Resources (ASX: LKY): Mojave Exploration Halt Hits Sentiment as Sellers Retake Control
Locksley Resources faces investor pressure after pausing Mojave exploration activities. The company is reassessing project spending, focusing on preserving assets, and reviewing future opportunities across its critical minerals portfolio.
.webp&w=828&q=75)
Austral Resources Australia (ASX: AR1): Stock Tests Resistance with Copper Growth in Focus
Austral Resources is drawing fresh attention through its Rocklands restart plans, Hammer Metals acquisition, copper exploration results, and infrastructure investment, while AR1’s chart approaches an important resistance zone with speculative risks still in focus.
.webp&w=828&q=75)
Austal (ASX: ABS): Breaks Downtrend with Defence Contracts in Focus
Austal (ASX: ASB) gains investor attention after Hanwha’s proposal for Austal USA, alongside major defence contracts and a technical breakout. The company faces both strategic opportunities and execution risks as its shipbuilding plans evolve.
.webp&w=828&q=75)
Centuria Office REIT (ASX: COF): Earnings Hold Firm, but Sellers Still Control the Trend
Centuria Office REIT is improving leasing, refinancing debt and stabilising property values, but lower FY27 distributions and high gearing remain concerns. COF now sits near key support as investors weigh stronger operations against lingering office market risks.
.webp&w=828&q=75)
Predictive Discovery (ASX: PDI): Strong Gold Output and Cash Growth Drive the Price Toward Resistance
Predictive Discovery has become a cash-generating West African gold producer following its Robex merger. Strong June output, rising cash reserves, Bankan engineering progress and regional expansion are strengthening its growth case, though permitting, cost and execution risks remain.
.webp&w=828&q=75)
Steadfast Group (ASX: SDF): Margin Growth and Global Expansion Through Cycle Resilience
Steadfast Group (ASX: SDF) delivers double‑digit EBITA growth, disciplined acquisitions, and margin expansion across Australasian and international operations, reinforcing its status as a resilient blue‑chip compounder.
Xenitra, ASX: XEN (formerly AuMake International): A Transformed Cross-Border Platform with a 290% Valuation Upside Potential
Xenitra (ASX: XEN) has transformed from a tourism-dependent retailer into a diversified cross-border platform connecting Australian and New Zealand health and consumer brands with Greater China. Revenue has grown roughly 15-fold from A$2.7m in FY23 to A$39.8m in FY25, while the company remains valued at only ~0.3x FY25 sales. With growth across nutritionals, OTC medicines and its OPAL platform, supported by major partnerships and favourable Chinese market tailwinds, Xenitra appears positioned for significant margin and earnings growth. A DCF valuation of A$0.0096–A$0.0137 per share implies substantial upside from the current A$0.003 share price.
.webp&w=828&q=75)
Benz Mining Corp. (ASX: BNZ): District‑Scale Gold Momentum and Structural Upside
Benz Mining Corp (ASX: BNZ) advances its Glenburgh Gold Project toward resource definition, delivering high‑grade intercepts, strong funding, and district‑scale potential that positions it as one of Australia’s most aggressive gold growth stories.
.webp&w=828&q=75)